Evaxion A/S (NASDAQ:EVAX) Receives “Buy” Rating from HC Wainwright

Evaxion A/S (NASDAQ:EVAX)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They presently have a $16.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 276.47% from the stock’s previous close.

Other research analysts have also issued research reports about the stock. JonesTrading assumed coverage on shares of Evaxion A/S in a report on Tuesday, March 10th. They issued a “buy” rating and a $10.00 price objective for the company. Wall Street Zen lowered shares of Evaxion A/S from a “buy” rating to a “hold” rating in a report on Sunday, March 22nd. Lake Street Capital dropped their price objective on shares of Evaxion A/S from $11.00 to $9.00 and set a “buy” rating for the company in a report on Monday, March 9th. Maxim Group assumed coverage on shares of Evaxion A/S in a report on Thursday, February 19th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Evaxion A/S in a report on Friday, January 9th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $11.00.

Evaxion A/S Stock Down 0.5%

EVAX stock opened at $4.25 on Friday. The stock has a market capitalization of $35.45 million, a P/E ratio of -3.22 and a beta of 0.19. The company has a current ratio of 5.85, a quick ratio of 5.85 and a debt-to-equity ratio of 0.41. Evaxion A/S has a 12 month low of $1.42 and a 12 month high of $12.15. The firm has a 50-day moving average price of $3.73 and a 200-day moving average price of $4.77.

Institutional Trading of Evaxion A/S

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. acquired a new stake in Evaxion A/S during the 4th quarter valued at approximately $38,000. Wesbanco Bank Inc. acquired a new stake in Evaxion A/S during the 4th quarter valued at approximately $48,000. Finally, SmartHarvest Portfolios LLC acquired a new stake in Evaxion A/S during the 4th quarter valued at approximately $72,000. Institutional investors and hedge funds own 11.04% of the company’s stock.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.